1-9 of 9
Huijing Wu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai
Journal: Blood
Blood (2024) 144 (Supplement 1): 6368.
https://doi.org/10.1182/blood-2024-211891
Published: 2024
Journal Articles

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Ruolan Zeng, Junqiao He, Yajun Li, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Yixue Li, Yinhua Liu, Weiqiang Tang, Qianying Ouyang, Liang Liang, Chang Su, Guige Lu, Xueting Zhu, Qianyu Hu, Zhou Ouyang, Huijing Wu, Huilai Zhang, Ling Xiao, Hui Zhou
Journal: Blood
Blood (2024) 144 (Supplement 1): 6355.
https://doi.org/10.1182/blood-2024-194674
Published: 2024
Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6145.
https://doi.org/10.1182/blood-2023-177820
Published: 2023
Journal Articles

A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

Yuqin Song, Zengjun Li, Huijing Wu, Jie Jin, Hui Zhou, Keshu Zhou, Liling Zhang, Zhigang Peng, Zhiye Zhang, Hong Cen, Youchao Jia, Yuerong Shuang, Zhiming Li, Haiyan Yang, Liqun Zou, Zhifeng Li, Zhihui Zhang, Junmin Li, Junning Cao, Lugui Qiu, Shaojie Wu, Tiejun Gong, Xiaohong Xu, Zhen Wang, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 306.
https://doi.org/10.1182/blood-2023-180137
Published: 2023
Journal Articles

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Hang Su, Tingyu Wang, Xiuhua Sun, Lihua Qiu, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1677.
https://doi.org/10.1182/blood-2023-178710
Published: 2023
Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 1689.
https://doi.org/10.1182/blood-2023-186252
Published: 2023
Journal Articles

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

Jie Jin, Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4430.
https://doi.org/10.1182/blood-2023-185543
Published: 2023
Journal Articles

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Fangfang Lyu, Junning Cao, Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6140.
https://doi.org/10.1182/blood-2023-180373
Published: 2023
Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Yan Gao, MD PhD, Huiqiang Huang, MDPhD, Xiaoxiao Wang, Bing Bai, Liling Zhang, MD PhD, Yin Xiao, Xinxiu Liu, Wenyu Li, PhD, Wei Xu, MD PhD, Ru Feng, Yu Chen, Huijing Wu, Jibin Li, Xue Wu
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-134665
Published: 2020